Fact CheckerSign in

NCT07427485Completed

Cognitive Rehabilitation With Immersive Virtual Reality (IVR) in Schizophrenia: a Pilot Randomized Waiting List Controlled Feasibility Study

Source: ClinicalTrials.gov · Last updated 15 Jun 2026

Brief summary (registry, in English)

Virtual reality-based rehabilitation has recently gained increasing attention in the field of cognitive rehabilitation, allowing patients to engage in simulated real-life scenarios within a safe and controlled setting. The feasibility and safety of immersive VR-based cognitive rehabilitation in individuals with schizophrenia is currently insufficiently explored. This study seeks to evaluate whether immersive immersive virtual reality-based rehabilitation can be safely and practically implemented in a community psychiatric setting. The study also aims to explore preliminary effects on negative symptoms, cognitive performance, and global functioning compared with treatment as usual in a waiting-list control group.

Status (registry)
Completed
Study type
Interventional
Enrollment
40 (actual)
First submitted
17 Feb 2026
Start date
Mar 2025
Primary completion date
Mar 2026
Lead sponsor
Azienda Sanitaria Locale Napoli 3 Sud, UOCSM Torre del Greco
NCT number
NCT07427485

What you commit to

  • Study type: Interventional
  • Participants enrolled: 40
  • From Mar 2025 to the primary completion date, Mar 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Concomitant intellectual disability or neurological disorders (e.g., neurodegenerative disorders, Parkison's disease, brain cancer) that may impair the ability to undergo cognitive rehabilitation

Other illness

  • Acute phase of illness

Other

  • Recent substance use (less than six months)
  • With a recent (less than six weeks from the enrolling date) symptom exacerbation, hospitalization or change in pharmacotherapy

Who the study is looking for

  • Individuals with Schizophrenia/Schizoaffective Disorder (DSM-5-TR)
  • Age 18-67 years
  • Chronic phase of illness
  • Able to provide a valid informed consent

Age in the registry: 18 years to 67 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Azienda Sanitaria Locale Napoli 3 Sud Unità Operativa Complessa Salute Mentale Torre del Greco/Ercolano
Coordinator of this site? Confirm its status
Torre del GrecoItalyUnknown status

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.